Quick answer
How is insulin resistance measured in MOTS-c research? The 2015 discovery paper reported that MOTS-c regulates insulin sensitivity and metabolic homeostasis and that exposure in mice prevented age-dependent and high-fat-diet-induced insulin resistance. Whether such a claim holds depends on the test behind it: glucose tolerance, insulin tolerance, hyperinsulinemic-euglycemic clamp, or cell-level glucose handling. This article explains what each test measures, summarizes what MOTS-c papers and related cohort studies reported, and lists the controls that make each result interpretable. It covers published laboratory work only. MOTS-c is supplied for laboratory research use only.
Why the test matters more than the headline
"Improved glucose metabolism" can mean several things: lower fasting glucose, faster clearance after a glucose load, a larger response to an insulin challenge, or higher glucose uptake in a particular tissue. Different tests answer different questions, and consortium guidelines exist precisely because mouse glucose tests can be designed and reported in ways that make results incomparable.[1] This page therefore organizes the MOTS-c findings by test type. The compound profile is in the MOTS-c research overview; this guide is about the measurement.
The tests and what each one measures
| Test | What it measures | Strength | Main limitation |
|---|---|---|---|
| Fasting glucose and insulin | Basal state | Simple; allows a surrogate index | Indirect; sensitive to fasting length |
| Glucose tolerance test | Clearance after a glucose load | Integrates secretion and sensitivity | Cannot separate insulin secretion from insulin action |
| Insulin tolerance test | Response to an insulin challenge | Direct readout of insulin action | Counter-regulatory responses confound the later time points |
| Hyperinsulinemic-euglycemic clamp | Glucose infusion needed to hold glucose steady | Reference method for insulin sensitivity | Technically demanding; small numbers |
| Isolated tissue or cell uptake | Glucose uptake in muscle, fat or cultured cells | Tissue-specific | Ex vivo conditions differ from the animal |
The mouse metabolic phenotyping consortium paper discusses issues in the design and performance of these tests and proposes guidelines for describing methods, presenting data and interpreting results.[1] Following those descriptions makes a MOTS-c study readable by others.
What the MOTS-c papers reported
| Paper | Model | Reported finding on glucose or insulin sensitivity |
|---|---|---|
| Lee 2015[2] | Mice | MOTS-c exposure prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity; skeletal muscle appears to be the primary target; AMPK activated via folate-cycle and purine-synthesis inhibition |
| Lu 2019[3] | Ovariectomized mice | Prevented ovariectomy-induced body-weight gain and insulin resistance; reduced fat mass; sustained brown fat activity; AMPK pathway involvement |
| Reynolds 2021[4] | Mice of three ages | Regulation of skeletal muscle metabolism and nuclear genes; enhanced physical performance |
| Kim 2018[5] | Cells | Nuclear translocation and gene regulation under glucose restriction, AMPK-dependent |
The two papers with insulin-resistance endpoints reached them in different mouse models, one driven by diet and age and the other by loss of ovarian hormones. Both linked the effect to AMPK, which gives the finding a common mechanism but not yet a common test: the abstracts do not specify which tolerance or clamp procedure was used in each model, so a reader needs the full methods before comparing sizes of effect.
Human cohort data: association, not mechanism
A cross-sectional study of 225 subjects measured serum concentrations of mitochondrial-derived peptides, including MOTS-c, and adiponectin in normal, pre-diabetes and type 2 diabetes groups, and its title reports that the peptides were lower in diabetes subjects.[6] A separate line of human physiology research, a clamp and spectroscopy study in young, lean, insulin-resistant offspring of people with type 2 diabetes, reported impaired mitochondrial activity in those insulin-resistant individuals.[7] These studies connect mitochondrial biology and insulin resistance in people at the level of association. They do not test MOTS-c as an intervention, and nothing in them is a claim about the research material supplied by V8.
Designing a glucose-handling experiment in the laboratory
- Declare the fasting protocol. Length of fast changes baseline glucose and insulin; state it and keep it constant between arms.
- Randomize and blind the order of animals or wells.
- Match body weight or adiposity between groups, or report it, because insulin sensitivity tracks adiposity.
- Use a vehicle arm on the same schedule and handled identically.
- Add an AMPK tool-compound arm only with the caveats described in the companion article on MOTS-c and AMPK assays.
- Report the whole curve, not only a single time point or an area under the curve.
- Document the material. Lot, purity, COA entry and storage conditions; compare with the COA library where a lot is published.
Reading curves, not single numbers
A glucose tolerance curve has a peak, a time to peak and a return toward baseline, and summarizing it with one area-under-the-curve number hides which part changed. A lower peak suggests faster early clearance or stronger early secretion; a faster return suggests better disposal; a higher baseline shifts the whole curve and should be handled by baseline correction or by reporting incremental area separately. Insulin tolerance curves are usually normalized to starting glucose, which is why animals with different baselines can show different shapes. Plot individual animals as well as group means, state the statistical model and report exclusions with their reasons. These habits make a modest effect checkable and a large one credible.
Cell-level glucose handling
For cultured myotubes or adipocytes the equivalent measures are glucose uptake with and without insulin, glycogen content and the phosphorylation state of insulin-signaling proteins. The same logic applies: a vehicle arm, a stimulated arm and a defined time course. Because glucose restriction was the stress used to study MOTS-c nuclear translocation,[5] the glucose concentration of the medium is a design variable that must be fixed and reported. Differentiation state matters too: undifferentiated and differentiated cells respond differently to insulin.
Pitfalls specific to glucose testing in peptide studies
Three pitfalls recur. First, repeated handling for peptide administration raises stress hormones, which raise glucose, so the vehicle arm must be handled in the same way and the same time of day. Second, the last administration should be timed consistently relative to the test, since a test run at peak and a test run at trough are different experiments. Third, body weight changes can move glucose handling by themselves, so a study that reports both outcomes should say whether the glucose effect persists after adjustment for body weight.
Concentration arithmetic, formula only
Concentration (mmol/mL) = mass (mg) ÷ molecular weight (g/mol) ÷ volume (mL), with about 2,175 g/mol for MOTS-c (formula C101H152N28O22S2, product page). Use the calculator. Published amounts in animal studies are per kilogram body weight and are not converted here. Two methionines in the sequence can oxidize, so prepare dilute solutions fresh and store lyophilized material at 2-8 °C or −20 °C for long-term storage as the product page states.
Research-use statement
All material discussed here is supplied for laboratory research use only; not for human or animal consumption, and not a drug, food or cosmetic.
Related reading
- MOTS-c research overview: the pillar guide
- MOTS-c product page: size, purity, lot COA and storage line
- What is MOTS-c peptide?
- MOTS-c vs other mitochondrial-derived peptides
- MOTS-c AMPK pathway research background
- MOTS-c nuclear translocation research background
- MOTS-c reconstitution and storage
- MOTS-c purity testing
- Browse all research compounds
Frequently asked questions
Which tests measure insulin sensitivity in mice?
Insulin tolerance tests and hyperinsulinemic-euglycemic clamps are direct; glucose tolerance tests integrate secretion and sensitivity.[1]
What did the 2015 paper report?
That MOTS-c exposure in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the apparent primary target organ.[2]
Was insulin resistance studied in other models?
In ovariectomized mice, MOTS-c exposure prevented obesity and insulin resistance according to the authors.[3]
Why is the clamp a reference method?
It holds blood glucose steady while insulin is infused, so the glucose infusion rate directly reflects insulin action.
Do human cohort studies show MOTS-c lowers glucose?
No. A cross-sectional study reported lower serum mitochondrial-derived peptide levels in diabetes subjects, which is an association.[6]
Why report the fasting protocol?
Fast length changes basal glucose and insulin, so groups must be compared under the same protocol.
Why control adiposity?
Insulin sensitivity tracks body fat, so unmatched groups can create or hide a difference.
How does glucose restriction relate to MOTS-c?
It was the stress used in the study of MOTS-c nuclear translocation.[5]
How is a stock calculated?
Mass in mg divided by about 2,175 g/mol, divided by volume in mL; use the calculator.
Is MOTS-c intended for people or animals?
No. It is supplied for laboratory research use only; not for human or animal consumption.
Related reading: MOTS-c in High-Fat-Diet Mice: Model Design Guide, MOTS-c Origin: A Peptide Encoded in Mitochondrial DNA, MOTS-c in Aged Mice: Published Findings on Physical Decline.
References
- Ayala JE, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010. doi:10.1242/dmm.006239 PMID: 20713647
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. doi:10.1016/j.cmet.2015.02.009 PMID: 25738459
- Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 2019. doi:10.1007/s00109-018-01738-w PMID: 30725119
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. doi:10.1038/s41467-020-20790-0 PMID: 33473109
- Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018. doi:10.1016/j.cmet.2018.06.008 PMID: 29983246
- Ramanjaneya M, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol. 2019. doi:10.3389/fendo.2019.00331 PMID: 31214116
- Petersen KF, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004. doi:10.1056/nejmoa031314 PMID: 14960743
